Heart drug trial halted after only 6 patients

NCT ID NCT04723186

Terminated Disease control Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a new drug called MT1002 in 6 people having a heart procedure (PCI) after a heart attack. The goal was to see if it could safely control blood clotting. However, the study was stopped early, so we don't have enough information to know if the drug works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MT1002 (an injectable drug to prevent blood clots during heart procedures)
What this could lead to: If it had worked, MT1002 might have offered a new option to control blood clotting during heart procedures, potentially reducing complications.
What could go wrong: This was a very small, early-phase trial that was terminated early, so we have little data on safety or effectiveness. The drug may not work or could cause serious bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME

Contacts and locations

Locations

IU Health - BMH

Muncie, Indiana, 47303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.